NCT06116032

Immune Profiling for Cancer Immunotherapy Response

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,500 (estimated)
• Sponsor: Dartmouth-Hitchcock Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Conditions

• Cancer
• Tumor, Solid
• Hematologic Malignancy
• Blood Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Methylation Cytometry	Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.

Timeline

• Start date: 2022-10-03
• Primary completion: 2027-01-01
• Completion: 2029-01-01
• First posted: 2023-11-03
• Last updated: 2025-12-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study